NuVasive (NUVA) recently announced its third-quarter earnings, and despite the OIG, subpoena related to Medicare/Medicaid false claims, it was able to surpass Wall Street's earnings expectations. Solid execution, the end of physician owned devices or PODs, and a maturing spine market allowed NuVasive to beat analysts' third quarter revenue expectations. Furthermore, the accelerating U.S. implant market and sales force stability are boosting NuVasive's stock price to gain further upside.
I expect the combination of NuVasive's lateral offering, robust development pipeline, physician/patient advocacy programs, and strong recent history of market share gains to facilitate the company to maintain its market-leading position and above-market growth rates. Furthermore, the fraud-alert issued by the OIG related to the business practices...
Only subscribers can access this article, which is part of the PRO research library covering 3,588 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: